ALPINE IMMUNE SCIENCES INC (ALPN) Fundamental Analysis & Valuation

NASDAQ:ALPN • US02083G1004

Current stock price

64.97 USD
+0.01 (+0.02%)
At close:
64.99 USD
+0.02 (+0.03%)
After Hours:

This ALPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ALPN Profitability Analysis

1.1 Basic Checks

  • ALPN had negative earnings in the past year.
  • ALPN had a negative operating cash flow in the past year.
  • In the past 5 years ALPN always reported negative net income.
  • In the past 5 years ALPN reported 4 times negative operating cash flow.
ALPN Yearly Net Income VS EBIT VS OCF VS FCFALPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of -9.86%, ALPN belongs to the best of the industry, outperforming 87.99% of the companies in the same industry.
  • With an excellent Return On Equity value of -11.07%, ALPN belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
Industry RankSector Rank
ROA -9.86%
ROE -11.07%
ROIC N/A
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
ALPN Yearly ROA, ROE, ROICALPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALPN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPN Yearly Profit, Operating, Gross MarginsALPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ALPN Health Analysis

2.1 Basic Checks

  • ALPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ALPN has more shares outstanding
  • There is no outstanding debt for ALPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALPN Yearly Shares OutstandingALPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ALPN Yearly Total Debt VS Total AssetsALPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 64.87 indicates that ALPN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ALPN (64.87) is better than 98.46% of its industry peers.
  • There is no outstanding debt for ALPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 64.87
ROIC/WACCN/A
WACC9.11%
ALPN Yearly LT Debt VS Equity VS FCFALPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

  • ALPN has a Current Ratio of 9.56. This indicates that ALPN is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 9.56, ALPN is doing good in the industry, outperforming 74.96% of the companies in the same industry.
  • ALPN has a Quick Ratio of 9.56. This indicates that ALPN is financially healthy and has no problem in meeting its short term obligations.
  • ALPN's Quick ratio of 9.56 is fine compared to the rest of the industry. ALPN outperforms 75.13% of its industry peers.
Industry RankSector Rank
Current Ratio 9.56
Quick Ratio 9.56
ALPN Yearly Current Assets VS Current LiabilitesALPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ALPN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.82% over the past year.
  • ALPN shows a strong growth in Revenue. In the last year, the Revenue has grown by 118.80%.
  • Measured over the past years, ALPN shows a very strong growth in Revenue. The Revenue has been growing by 141.96% on average per year.
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%

3.2 Future

  • Based on estimates for the next years, ALPN will show a very negative growth in Earnings Per Share. The EPS will decrease by -13.31% on average per year.
  • The Revenue is expected to grow by 33.81% on average over the next years. This is a very strong growth
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALPN Yearly Revenue VS EstimatesALPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
ALPN Yearly EPS VS EstimatesALPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALPN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALPN. In the last year negative earnings were reported.
  • Also next year ALPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPN Price Earnings VS Forward Price EarningsALPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPN Per share dataALPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as ALPN's earnings are expected to decrease with -54.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALPN Dividend Analysis

5.1 Amount

  • ALPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ALPN Fundamentals: All Metrics, Ratios and Statistics

ALPINE IMMUNE SCIENCES INC

NASDAQ:ALPN (5/17/2024, 8:00:01 PM)

After market: 64.99 +0.02 (+0.03%)

64.97

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09
Earnings (Next)08-12
Inst Owners5.3%
Inst Owner Change0%
Ins Owners18.43%
Ins Owner Change0%
Market Cap4.46B
Revenue(TTM)56.52M
Net Income(TTM)-36.84M
Analysts76
Price Target62.73 (-3.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84.33%
Min EPS beat(2)33.62%
Max EPS beat(2)135.04%
EPS beat(4)4
Avg EPS beat(4)56.9%
Min EPS beat(4)29.29%
Max EPS beat(4)135.04%
EPS beat(8)5
Avg EPS beat(8)-18.51%
EPS beat(12)5
Avg EPS beat(12)-928.68%
EPS beat(16)6
Avg EPS beat(16)-710.5%
Revenue beat(2)2
Avg Revenue beat(2)164.17%
Min Revenue beat(2)96.1%
Max Revenue beat(2)232.25%
Revenue beat(4)3
Avg Revenue beat(4)89.84%
Min Revenue beat(4)-4.81%
Max Revenue beat(4)232.25%
Revenue beat(8)4
Avg Revenue beat(8)23.35%
Revenue beat(12)5
Avg Revenue beat(12)4.08%
Revenue beat(16)6
Avg Revenue beat(16)-4.07%
PT rev (1m)-0.81%
PT rev (3m)83.19%
EPS NQ rev (1m)3.87%
EPS NQ rev (3m)-9.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-35.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.86
P/FCF N/A
P/OCF N/A
P/B 13.4
P/tB 13.4
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.82
BVpS4.85
TBVpS4.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.86%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.36%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.56
Quick Ratio 9.56
Altman-Z 64.87
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)57.41%
Cap/Depr(5y)96.93%
Cap/Sales(3y)0.9%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%
EBIT growth 1Y22.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.67%
EBIT Next 3Y-35.27%
EBIT Next 5Y-25.05%
FCF growth 1Y-1436.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1405.54%
OCF growth 3YN/A
OCF growth 5YN/A

ALPINE IMMUNE SCIENCES INC / ALPN Fundamental Analysis FAQ

What is the fundamental rating for ALPN stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALPN.


What is the valuation status for ALPN stock?

ChartMill assigns a valuation rating of 0 / 10 to ALPINE IMMUNE SCIENCES INC (ALPN). This can be considered as Overvalued.


Can you provide the profitability details for ALPINE IMMUNE SCIENCES INC?

ALPINE IMMUNE SCIENCES INC (ALPN) has a profitability rating of 2 / 10.


What is the financial health of ALPINE IMMUNE SCIENCES INC (ALPN) stock?

The financial health rating of ALPINE IMMUNE SCIENCES INC (ALPN) is 8 / 10.


What is the earnings growth outlook for ALPINE IMMUNE SCIENCES INC?

The Earnings per Share (EPS) of ALPINE IMMUNE SCIENCES INC (ALPN) is expected to decline by -157.63% in the next year.